Smart medical device designer and manufacturer, EVEON,  and virtual trials & digital therapeutics platform, BEPATIENT, announce an exciting new strategic partnership.

Paris and Grenoble (France), 18th May, 2021BEPATIENT, a pioneer in the development of virtual trials and digital therapeutics solutions, has signed a collaboration agreement with EVEON, designer and manufacturer of smart medical devices. The partnership will produce patient-centric digital solutions that serve both clinical research and digital therapeutics applications.

EVEON is a key player to make easily accessible molecules and new medicines, particularly with complex preparation or administration (biologics, lyophilisate to be reconstituted, dispersing powder, suspensions, dilutions, emulsions, combinations of therapies, highly viscous formulations, etc.)  to the largest number of people. EVEON focuses on the design, development and industrialization of tailor-made connected medical devices for both drug preparation and drug delivery. In the context of this partnership, their unique technology Intuity ®, which guarantees safety and ease of use, will be used.  Their innovative solutions can also be used to split doses of drugs in liquid form and perform multi-dose administrations using a single vial.

Meanwhile, BEPATIENT’s proprietary eHealth platform has been in agile development for more than ten years, and has produced innovations that enable direct-to-patient data collection for virtual clinical trials, as well as patient support, engagement and remote monitoring solutions for new digital therapies.

This new collaboration will integrate EVEON’s connected medical device into the BEPATIENT core platform, with a view to enabling tracking and remote management of medication adherence, and facilitating the handling, preparation and administration of specific drugs, in the context of both virtual clinical trials and digital therapeutics programs.

Read the full press release

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *